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PET/CT Radiomic Sequencer for Prediction of EGFR and 
KRAS Mutation Status in NSCLC Patients 
 Abstract: 
The aim of this study was to develop radiomic models using PET/CT radiomic features with different 
machine learning approaches for finding best predictive epidermal growth factor receptor (EGFR) and 
Kirsten rat sarcoma viral oncogene (KRAS) mutation status. Patient’s images including PET and CT 
[diagnostic (CTD) and low dose CT (CTA)] were pre-processed using wavelet (WAV), Laplacian of 
Gaussian (LOG) and 64 bin discretization (BIN) (alone or in combinations) and several features from images 
were extracted. The prediction performance of model was checked using the area under the receiver operator 
characteristic (ROC) curve (AUC). Results showed a wide range of radiomic model AUC performances up 
to 0.75 in prediction of EGFR and KRAS mutation status. Combination of K-Best and variance threshold 
feature selector with logistic regression (LREG) classifier in diagnostic CT scan led to the best performance 
in EGFR (CTD-BIN+B-KB+LREG, AUC: 0.75±0.10) and KRAS (CTD-BIN-LOG-WAV+B-VT+LREG, 
AUC: 0.75±0.07) respectively. Additionally, incorporating PET, kept AUC values at ~0.74. When 
considering conventional features only, highest predictive performance was achieved by PET SUVpeak 
(AUC: 0.69) for EGFR and by PET MTV (AUC: 0.55) for KRAS. In comparison with conventional PET 
parameters such as standard uptake value, radiomic models were found as more predictive. Our findings 
demonstrated that non-invasive and reliable radiomics analysis can be successfully used to predict EGFR and 
KRAS mutation status in NSCLC patients. 
 
 
I. INTRODUCTION 
MOLECULAR Profiling is a standard protocol for 
better management of non-small cell lung cancer 
(NSCLC) patients. Analyses of the mutation status of 
epidermal growth factor receptor (EGFR) and 
Kirsten rat sarcoma viral oncogene (KRAS) 
mutations are frequently performed and used as 
management tools in non-small cell lung cancer 
(NSCLC) [1]. Accumulating evidence has suggested 
that mutations in KRAS and EGFR are considered as 
first lines for clinical decision making in NSCLS 
treatment and outcome improvement [2]. 
Radiomics is a new advanced approach aiming to 
find correlation between features extracted from 
medical images and clinical/biological data[3]. 
Image features have the potential to be used in a wide 
range of clinical applications including tumor 
characterization, staging, grading, therapy response 
assessment and prediction[4]. Based on advanced 
radiomics studies, converting images to high-
dimensional, mineable, and quantitative data could 
provide an advanced, low cost and noninvasive to 
improve decision-support in clinics [5]. However 
                                                 
 
radiomics studies suffer from several challenges, and 
a robust framework for clinical decision making is 
highly desired [6-11]. 
Studies on radiomic modelling have been made by 
using advanced algorithms such as machine learning 
(ML) approaches [12]. Previous works have tested 
several ML algorithms and identified that some 
algorithms can contribute to build highly accurate 
and reliable predictive and prognostic radiomic 
models [12].  
Recently some studies have indicated that 
imaging features extracted from CT scan images 
could predict mutation status in NSCLC patients. 
Velazquez et al. [13] developed radiomic models 
based on CT image features and clinical parameters 
to distinguish between EGFR- and EGFR+, and 
KRAS+ and KRAS. Liu et al. [14] also, evaluated the 
capability of CT image features to predict EGFR 
mutation status in 298 surgically-resected peripheral 
lung adenocarcinomas in an Asian cohort of patients 
and build a high performance predictive model by 
using multiple logistic regression algorithm. Zhang 
et al. [15] also developed a radiogenomic model 
based on CT image features to predict EGFR and 
KRAS mutations in lung adenocarcinoma patients.  
In the present work, we aimed to develop 
predictive models using PET, CT, and PET/CT 
image radiomic features with different machine 
learning approaches for optimal prediction of KRAS 
and EGFR mutation status. 
 
 
II. METHODS 
 
A. Image Data-Set  
We considered 211 NSCLS cancer patients, each 
including diagnostic CT (CTD), low dose CT (CTA) 
and PET, as well as mutation status for KRAS and 
EGFR. After applying including/excluding criteria, 
186 patients manually segmented on PET images, 
175 patients manually segmented on CTA & CTD. 
 
B. Image Pre-Processing  
Pre-processing include Laplacian of Gaussian 
(LOG), wavelet decomposition (WAV) and 
discretization to 64 bin (BIN64) were applied alone 
or in combinations on images.  For LOG filter, 
different sigma value used to extract fine, medium 
and coarse (sigma value 0.5 to 5 with 0.5 steps) 
features.  
 
C. Feature Extraction 
After applying pre-processing filters, image 
dataset was prepared and several radiomic features 
from different feature sets were extracted. The main 
feature sets were including; first order statistics and 
SUV based (19 features), Shape-based (16 features), 
gray level co-occurrence matrix (GLCM; 23 
features), gray level run length matrix (GLRLM; 16 
features), gray level size zone matrix (GLSZM; 16 
features), neighboring gray tone difference matrix 
(NGTDM; 5 features), and gray level dependence 
matrix (GLDM; 14 features).  
 
D. Machine Learning 
In this study, we used different algorithms for data 
splitting, feature selection and classification.  
For feature selection, we used Select K Best (KB), 
Select K Best & Mutual Info Regression (KB-MIR), 
Select from Model (SM) and Variance Threshold & 
Select from Model (VT-SM). 
For data splitting 10-fold cross validation were 
used.  In the present work, we trained classifiers with 
two different methods; balance and un-balance. In 
balance method, we have equal data from each class, 
where as in un-balance, there is no equal data and 
data are selected randomly.  
 For classification, we used random forest 
(RF), Bagging (BG), Logistic Regression (LREG), 
Naïve Bayesian (NB) and Support Vector Machine 
(SVM). To develop predictive radiomic models, 
patients with mutation in KRAS and EGFR were 
considered as class with label (+) and no mutations 
were considered with label (-). 
 
E. Statistical Analysis 
All analysis including feature selection and 
classification were performed by in house developed 
python codes. The prediction ability of model was 
checked using the area under the receiver operator 
characteristic (ROC) curve (AUC). 
 
 
 
III. RESULTS 
 
Our results for EGFR mutation status prediction 
based on feature selection methods and image sets 
are depicted in Fig. 1-a (mean AUC). It can be 
deduced from Fig. 1-a that feature selection 
performance had a small range from 0.53 to 0.6, and 
the combination of SM+PET-WAV had the highest 
performance (AUC:  0.60). 
Fig. 1-b shows our results regarding EGFR mutation 
status prediction based on classifier and image sets. 
According to these results, classification 
performance has a range from 0.50 to 0.67 and 
combination of NB+CTD-BIN-LOG-WAV had the 
highest performance (AUC: 0.67). 
 
 
 
 
 
 
Fig. 1. Prediction of EGFR mutation status (in term 
of AUC), Rows; image sets Columns; a) feature 
selection b) Classifier  
 
 
(b) (a) 
Fig. 2-a, show KRAS mutation status prediction 
results based on feature selection methods and image 
sets. In these results, feature selection performance 
has a small range from 0.52 to 0.56, and the 
combination of SM+PET-CT had the highest 
performance (AUC: 56). 
KRAS mutation status prediction results based on 
feature classification and image sets is presented in 
Fig. 2-b (mean AUC). Here, the classification 
performance has a range from 0.50 to 0.62 and 
combination of SVM+PET-CT had the highest 
performance (AUC: 0.62). 
 
 
 
 
 
 
  
Fig. 2. Prediction of KRAS mutation status (in term 
of AUC), Rows; image sets Columns; a) feature 
selection b) classification  
 
Fig. 3 depicts the ROC curves of the best predictive 
models in both machine learning and conventional 
clinical PET features. We further observed that the 
combination method CTD-BIN+B-KB+LREG 
(AUC: 0.75±0.10) had the highest predictive 
performance, followed by PET-CTD+B-VT-
KB+MIR-SVM (AUC: 0.74±13), PET-CTD+B-
KB+MIR-SVM (AUC: 0.74±13) lead to best 
performance in EGFR. Also, for KRAS CTD-BIN-
LOG-WAV+B-VT-KB+MIR-LREG (AUC: 
0.75±0.08) and CTD-BIN-LOG-WAV+B-VT+ 
LREG (AUC: 0.75±0.07) had the best performance.  
 
Our univariate analysis on conventional PET models 
(ROC curves in Fig. 3 for mutation status prediction 
showed that SUVpeak (AUC=0.69) and MTV (AUC: 
0.55) had the highest performance for EGFR and 
KRAS respectively. 
 
 
 
 
 
 
 
 
(b) (a) 
  
 
 
 
 
 
 
 
 
 
Fig. 3.  ROC curve of prediction in machine learning algorithm (A, B) and conventional PET features (C, D), Top Row; EGFR, Bottom Row; KRAS, Error bars (shading region); 
10-fold cross validation in machine learning algorithm 
 
IV. DISCUSSION 
 
Predictive radiomic modeling is an active area of 
research in personalized medicine. In recent years a 
wide range of retrospective/prospective researches 
have been made on radiomics correlating 
phonotypical features with genomic status [1].  
In the present study we developed radiomic 
signatures predictive of mutational status in NSCLC 
patients that showed good predictive performance in 
some imaging modalities. For EGFR and KRAS 
mutation status prediction a cross combination of 
imaging/ validation/ feature selection/ Classification 
methods resulted in a wide range of performance 
(AUC: 0.5~0.75). 
In the present study, we developed sequencer 
radiomic models based on different image sets, pre-
processing, feature selection, and classifier. This 
sequencing approach will result in a wide range of 
predictive models with different performances. In 
this situation, care should be taken into account for 
selecting the best models. 
 Some previous radiomics studies have tested 
different machine learning algorithms for 
introducing the best methods for feature selection 
and classifier[16]. Parmer et al. [17] by comparing 
fourteen feature selection and twelve classification 
methods in terms of their performance and stability 
found that WLCX (feature selection) and random 
forest (classification) had the highest prognostic 
performance with high stability against data 
perturbation. Zhang et al. [18], also, build a 54 cross 
combination machine learning algorithms including 
six feature selection and nine classification methods 
for survival prediction of advanced nasopharyngeal 
carcinoma. They found that the combination 
methods Random Forest (RF) and RF had the highest 
prognostic performance, followed by RF+Adaptive 
Boosting and Sure Independence Screening (SIS) + 
Linear Support Vector Machines.  
In our results, we compared the conventional PET 
parameters (MTV, SUV and SUL) with radiomic 
features. We showed that radiomic models are more 
predictive than conventional clinical PET 
parameters. In our radiogenomic study, we found 
that also, the combination of PET and CT image 
features could better predict gene mutation status 
rather than parameters including SUV or MTV.  
This study is showed, EGFR and KRAS mutation 
prediction using PET, CT and their combinations and 
be considered as a feasible and prospective approach 
for clinical decision making. In comparison with 
previous studies, our results seem to be consistent 
and comparable.  
 
V. CONCLUSION 
 
In conclusion, the results presented here show the 
ability of PET, CT and PET/CT radiomic features to 
predict mutation status in cancer patients. This study 
incorporated PET images in lung cancer patients to 
find a link between PET/CT quantitation and 
genomics. The results indicate the potential of 
radiogenomics analysis to predict mutation statues in 
NSCLC PET/CT images in non-invasive manner. 
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